Drug Profile
Wetimicin
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Aida Pharmaceuticals
- Class Aminoglycosides; Antibacterials
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Bacterial-infections in China (IV)
- 27 Apr 2011 Clinical trials in Bacterial infections in China (IV)
- 11 Apr 2008 Phase-I clinical trials in Bacterial infections in China (IV)